Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp64199_8k.htm |
Exhibit 99.1
| Press Release |  |
| www.shire.com |
Director/PDMR Shareholding
March 14, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that on March 11, 2016, Restricted Stock Units (“RSUs”) were granted to Persons Discharging Managerial Responsibilities (“PDMRs”) under the Shire Deferred Bonus Plan 2015 (“DBP”). The RSUs, which are in respect of notional American Depositary Shares (“ADSs”), will normally vest after three years. No consideration was paid for these awards.
| PDMR | Number of ADSs |
| Flemming Ornskov | 4,245 |
| Mark Enyedy | 1,059 |
| Ginger Gregory | 644 |
| Bill Mordan | 155 |
| Phil Vickers | 877 |
The DBP is a sub-plan of the Shire Long
Term Incentive Plan 2015. The DBP has replaced the Shire Executive Annual Incentive Plan as referenced in the 2014 Annual Report
and Accounts. One ADS is equal to three Ordinary Shares of 5 pence each in the Company.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX